Cargando…

Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection

OBJECTIVE: This study aimed to analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for locoregional recurrent pancreatic cancer after radical resection. METHODS: Patients with locoregional recurrent pancreatic cancer after surgery treated with SBRT in our institution were retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Xiaoqin, Zhou, Bin, Ding, Wei, Wang, Jiasheng, Jiang, Wanrong, Li, Yikun, Hu, Jun, Sun, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353056/
https://www.ncbi.nlm.nih.gov/pubmed/35936670
http://dx.doi.org/10.3389/fonc.2022.925043
_version_ 1784762790408355840
author Ji, Xiaoqin
Zhou, Bin
Ding, Wei
Wang, Jiasheng
Jiang, Wanrong
Li, Yikun
Hu, Jun
Sun, Xiangdong
author_facet Ji, Xiaoqin
Zhou, Bin
Ding, Wei
Wang, Jiasheng
Jiang, Wanrong
Li, Yikun
Hu, Jun
Sun, Xiangdong
author_sort Ji, Xiaoqin
collection PubMed
description OBJECTIVE: This study aimed to analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for locoregional recurrent pancreatic cancer after radical resection. METHODS: Patients with locoregional recurrent pancreatic cancer after surgery treated with SBRT in our institution were retrospectively investigated from January 2010 to January 2020. Absolute neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) recorded at pretreatment were analyzed. Endpoints included overall survival (OS), progression-free survival (PFS) and cumulative incidences of local failure (LF) and metastatic failure (MF). RESULTS: A total of 22 patients received SBRT with a median prescribed dose of 40 Gy (range of 30-50 Gy)/4 to 7 fractions. The median OS of all patients was 13.6 months (95% CI, 9.6-17.5 months). 0-1 performance status (HR 12.10, 95% CI 2.04-71.81, P=0.006) and ≤2.1 pre-SBRT NLR (HR 4.05, 95% CI 1.21-13.59, P=0.023) were significant predictors of higher OS on multivariable analysis. The median progression-free survival (PFS) of the cohort was 7.5 months (95% CI, 6.5-8.5 months). The median time to LF and MF were 15.6 months and 6.4 months, respectively. The rate of MF as a first event was higher than that of first event LF. Pain relief was observed in all patients (100%) 6 weeks after SBRT. In terms of acute toxicity, grade 1 including fatigue (6, 27.3%), anorexia (6, 27.3%), nausea (4, 18.2%) and leukopenia (4, 18.2%) was often observed. No acute toxicity of grade 4 or 5 was observed. In terms of late toxicity, no treatment-related toxicity was found during follow-up. CONCLUSION: This study showed that SBRT can significantly reduce pain, effectively control local tumor progression, and have acceptable toxicity for patients with locoregional recurrence after radical resection of primary pancreatic cancer. Good performance status and lower pre-SBRT NLR were associated with improved overall survival.
format Online
Article
Text
id pubmed-9353056
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93530562022-08-06 Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection Ji, Xiaoqin Zhou, Bin Ding, Wei Wang, Jiasheng Jiang, Wanrong Li, Yikun Hu, Jun Sun, Xiangdong Front Oncol Oncology OBJECTIVE: This study aimed to analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for locoregional recurrent pancreatic cancer after radical resection. METHODS: Patients with locoregional recurrent pancreatic cancer after surgery treated with SBRT in our institution were retrospectively investigated from January 2010 to January 2020. Absolute neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) recorded at pretreatment were analyzed. Endpoints included overall survival (OS), progression-free survival (PFS) and cumulative incidences of local failure (LF) and metastatic failure (MF). RESULTS: A total of 22 patients received SBRT with a median prescribed dose of 40 Gy (range of 30-50 Gy)/4 to 7 fractions. The median OS of all patients was 13.6 months (95% CI, 9.6-17.5 months). 0-1 performance status (HR 12.10, 95% CI 2.04-71.81, P=0.006) and ≤2.1 pre-SBRT NLR (HR 4.05, 95% CI 1.21-13.59, P=0.023) were significant predictors of higher OS on multivariable analysis. The median progression-free survival (PFS) of the cohort was 7.5 months (95% CI, 6.5-8.5 months). The median time to LF and MF were 15.6 months and 6.4 months, respectively. The rate of MF as a first event was higher than that of first event LF. Pain relief was observed in all patients (100%) 6 weeks after SBRT. In terms of acute toxicity, grade 1 including fatigue (6, 27.3%), anorexia (6, 27.3%), nausea (4, 18.2%) and leukopenia (4, 18.2%) was often observed. No acute toxicity of grade 4 or 5 was observed. In terms of late toxicity, no treatment-related toxicity was found during follow-up. CONCLUSION: This study showed that SBRT can significantly reduce pain, effectively control local tumor progression, and have acceptable toxicity for patients with locoregional recurrence after radical resection of primary pancreatic cancer. Good performance status and lower pre-SBRT NLR were associated with improved overall survival. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353056/ /pubmed/35936670 http://dx.doi.org/10.3389/fonc.2022.925043 Text en Copyright © 2022 Ji, Zhou, Ding, Wang, Jiang, Li, Hu and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ji, Xiaoqin
Zhou, Bin
Ding, Wei
Wang, Jiasheng
Jiang, Wanrong
Li, Yikun
Hu, Jun
Sun, Xiangdong
Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
title Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
title_full Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
title_fullStr Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
title_full_unstemmed Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
title_short Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
title_sort efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353056/
https://www.ncbi.nlm.nih.gov/pubmed/35936670
http://dx.doi.org/10.3389/fonc.2022.925043
work_keys_str_mv AT jixiaoqin efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection
AT zhoubin efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection
AT dingwei efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection
AT wangjiasheng efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection
AT jiangwanrong efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection
AT liyikun efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection
AT hujun efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection
AT sunxiangdong efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection